Patiromer 1000 MG Powder for Oral Suspension [Veltassa] — RxCUI 2692052
RxNorm drug concept · Semantic branded drug
RxCUI 2692052
Semantic branded drug · SBD
● Current RxNorm concept 4 FDA products
6 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2692052
Official namePatiromer 1000 MG Powder for Oral Suspension [Veltassa]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asVeltassa 1 GM Powder for Oral Suspension; Veltassa 1000 MG Powder for Oral Suspension
FDA products mapped4
Package NDCs mapped6
Reported Medicaid activity (SDUD)13,474 prescriptions · 34 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Patiromer: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Think of Veltassa as a sponge that you swallow. It travels through your gut, latches onto excess potassium in your intestines, and carries it out of your body in your stool. It nev...
- What exactly is Veltassa doing in my body?
- Mix the packet of powder into about a third of a cup of water — or a soft food like applesauce or yogurt — right before you take it. Stir it well, drink it immediately, and if powd...
- How do I mix and take this medication correctly?
🕸️ Concept Web — How Patiromer 1000 MG Powder for Oral Suspension [Ve... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Patiromer 1000 MG Powder for Oral Suspension [Veltassa]
RxCUI 2692052 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Patiromer
1716203IN
-
Patiromer
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Veltassa
1716210BN
-
Veltassa
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Patiromer Powder for Oral Suspension
1716208SCDF -
Patiromer Oral Powder Product
1716206SCDG -
Patiromer Oral Product
1716207SCDG -
Patiromer Powder for Oral Suspension [Veltassa]
1716212SBDF -
Veltassa Oral Powder Product
1716213SBDG -
Veltassa Oral Product
1716214SBDG -
Powder for Oral Suspension
1540456DF -
Oral Powder Product
1294711DFG - +1 more in this family
-
Patiromer Powder for Oral Suspension
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Patiromer 1000 MG Powder for Oral Suspension
2692050SCD -
Patiromer 1000 MG
2692049SCDC -
Patiromer 1000 MG [Veltassa]
2692051SBDC
-
Patiromer 1000 MG Powder for Oral Suspension
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Patiromer 1000 MG Powder for Oral Suspension
SCD · 2692050 -
Patiromer 1000 MG
SCDC · 2692049 -
Patiromer Powder for Oral Suspension
SCDF · 1716208 -
Patiromer Oral Powder Product
SCDG · 1716206 -
Patiromer Oral Product
SCDG · 1716207
Brand-Name Concepts
-
Patiromer 1000 MG [Veltassa]
SBDC · 2692051 -
Patiromer Powder for Oral Suspension [Veltassa]
SBDF · 1716212 -
Veltassa Oral Powder Product
SBDG · 1716213 -
Veltassa Oral Product
SBDG · 1716214 -
Veltassa
BN · 1716210
📦 FDA Products & Package NDCs
4 products · 6 package NDCs
6 package NDCs map to RxCUI 2692052 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 53436-0010-60 | 60 PACKET in 1 CARTON (53436-010-60) / 1 POWDER, FOR SUSPEN... | VELTASSA | Vifor Pharma, Inc. | 2024-10-02 |
| 53436-0084-04 | 4 PACKET in 1 CARTON (53436-084-04) / 1 POWDER, FOR SUSPENS... | VELTASSA | Vifor Pharma, Inc. | 2015-10-23 |
| 53436-0084-30 | 30 PACKET in 1 CARTON (53436-084-30) / 1 POWDER, FOR SUSPEN... | VELTASSA | Vifor Pharma, Inc. | 2015-10-23 |
| 53436-0084-92 | 4 PACKET in 1 CARTON (53436-084-92) / 1 POWDER, FOR SUSPENS... | VELTASSA | Vifor Pharma, Inc. | 2016-05-01 |
| 53436-0168-30 | 30 PACKET in 1 CARTON (53436-168-30) / 1 POWDER, FOR SUSPEN... | VELTASSA | Vifor Pharma, Inc. | 2015-10-23 |
| 53436-0252-30 | 30 PACKET in 1 CARTON (53436-252-30) / 1 POWDER, FOR SUSPEN... | VELTASSA | Vifor Pharma, Inc. | 2015-10-23 |
Observed labelers:
Vifor Pharma, Inc. (6)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.